These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Retrospective cross-sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy. Lyon KC; Likar E; Martello JL; Regier M J Gastroenterol Hepatol; 2017 Sep; 32(9):1548-1552. PubMed ID: 28177545 [TBL] [Abstract][Full Text] [Related]
64. Rifaximin: a nonsystemic antibiotic for hepatic encephalopathy. Welliver M Gastroenterol Nurs; 2013; 36(2):140-2. PubMed ID: 23549218 [No Abstract] [Full Text] [Related]
65. Heretical thoughts into hepatic encephalopathy. Jalan R; Rose CF J Hepatol; 2022 Aug; 77(2):539-548. PubMed ID: 35358618 [TBL] [Abstract][Full Text] [Related]
66. [Update on the management of hepatic encephalopathy]. García Martínez R; Córdoba Cardona J Rev Esp Enferm Dig; 2008 Oct; 100(10):637-44. PubMed ID: 19119790 [No Abstract] [Full Text] [Related]
67. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Pedretti G; Calzetti C; Missale G; Fiaccadori F Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811 [TBL] [Abstract][Full Text] [Related]
68. Rifaximin: new therapeutic indication and future directions. Rivkin A; Gim S Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091 [TBL] [Abstract][Full Text] [Related]
69. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins. Cacciottolo TM; Kingdon A; Alexander GJ Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1765. PubMed ID: 24703862 [No Abstract] [Full Text] [Related]
70. Treatment of hyperammonemia in liver failure. Jover-Cobos M; Khetan V; Jalan R Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376 [TBL] [Abstract][Full Text] [Related]
71. Will health insurers cover the costs? Muehlenberg K Dtsch Arztebl Int; 2012 Jul; 109(29-30):502; author reply 502-3. PubMed ID: 23056152 [No Abstract] [Full Text] [Related]
72. Restricting protein intake not beneficial. Plauth M Dtsch Arztebl Int; 2012 Jul; 109(29-30):502; author reply 502-3. PubMed ID: 23056151 [No Abstract] [Full Text] [Related]
73. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis]. Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887 [TBL] [Abstract][Full Text] [Related]
74. [Dilemmas of clinical experimentation: use of lactulose in portocaval encephalopathy]. Conn HO Union Med Can; 1974 Dec; 103(12):2058-60. PubMed ID: 4619236 [No Abstract] [Full Text] [Related]
75. Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients. Alvisi V; D'Ambrosi A; Loponte A; Pazzi P; Greco A; Zangirolami A; Palazzini E J Int Med Res; 1987; 15(1):49-56. PubMed ID: 3817281 [TBL] [Abstract][Full Text] [Related]